Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UU1E
|
|||
| Former ID |
DIB001363
|
|||
| Drug Name |
CC-100
|
|||
| Synonyms |
Fendosal; 53597-27-6; 5-(4,5-Dihydro-2-phenyl-3H-benz[e]indol-3-yl)salicylic acid; Alnovin; Fendosalum; HP 129; Fendosalum [INN-Latin]; UNII-9Z709558TZ; P 71-0129; C25H19NO3; NSC 351522; BRN 1665211; 2-hydroxy-5-(2-phenyl-4,5-dihydrobenzo[e]indol-3-yl)benzoic acid; 2-Hydroxy-5-(2-phenyl-4,5-dihydro-3H-benzo[e]indol-3-yl)benzoic acid; 3-(3-Carboxy-4-hydroxyphenyl)-2-phenyl-4,5-dihydro-3H-benz(e)indole; 5-(4,5-Dihydro-2-phenyl-3H-benz(e)indol-3-yl)-2-hydroxybenzoic acid; NSC351522; HP-129; 9Z709558TZ
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Amyotrophic lateral sclerosis [ICD-11: 8B60.0] | Phase 1 | [1] | |
| Motor neurone disease [ICD-11: 8B60; ICD-10: G12.2; ICD-9: 335.2] | Phase 1 | [2] | ||
| Company |
Chemigen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H19NO3
|
|||
| Canonical SMILES |
C1CC2=C(C=C(N2C3=CC(=C(C=C3)O)C(=O)O)C4=CC=CC=C4)C5=CC=CC=C51
|
|||
| InChI |
1S/C25H19NO3/c27-24-13-11-18(14-21(24)25(28)29)26-22-12-10-16-6-4-5-9-19(16)20(22)15-23(26)17-7-2-1-3-8-17/h1-9,11,13-15,27H,10,12H2,(H,28,29)
|
|||
| InChIKey |
HAWWPSYXSLJRBO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 53597-27-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
225464, 463558, 6344160, 8176805, 12012798, 15498612, 34706550, 47206092, 49886990, 57312472, 75705292, 104335401, 123392734, 126579738, 126634526, 126671719, 126737086, 128034422, 128034423, 135003931, 136378460, 136946572, 137241563, 143201270, 144115318, 152058957, 152212797, 160687292, 160815782, 162011449, 162183108, 163090224, 164824499, 172893125, 174474487, 179150574, 184546300, 186014382, 198938481, 202546924, 204388945, 223398561, 223558147, 223672997, 224770742, 226413168, 242059744, 249826503, 250197909, 252058223
|
|||
| ChEBI ID |
CHEBI:135595
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02050334) CC100: Safety and Tolerability of Single Doses. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.